Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Terminal insomnia19.02.01.004; 17.15.03.004--Not Available
Acute kidney injury20.01.03.016--
Upper-airway cough syndrome22.12.03.036--
Foetal growth restriction18.03.01.0020.000085%
Posterior reversible encephalopathy syndrome17.13.02.0070.000038%
Functional gastrointestinal disorder07.11.01.016--Not Available
Slow speech19.19.02.004; 17.02.08.0160.000038%Not Available
Post-traumatic neck syndrome15.03.04.017; 12.01.07.011; 17.10.02.004--Not Available
Drug-induced liver injury09.01.07.023; 12.03.01.0440.000152%Not Available
Reversible cerebral vasoconstriction syndrome24.04.06.026; 18.06.01.004; 17.08.02.0140.000408%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.000123%Not Available
Candida infection11.03.03.021--
Language disorder19.19.01.006; 17.02.08.0150.000019%Not Available
Peripheral venous disease24.04.02.0220.000028%Not Available
Intrusive thoughts19.10.03.0080.000019%Not Available
Depersonalisation/derealisation disorder19.14.01.0040.000047%Not Available
Alcohol interaction08.06.03.0030.000057%Not Available
Attention-seeking behaviour19.05.01.0160.000038%Not Available
Carcinoid syndrome05.08.02.005; 16.32.02.0040.000133%Not Available
Central nervous system lymphoma01.12.01.005; 18.04.04.013; 17.02.10.028; 16.20.01.0050.000019%Not Available
Cerebral haemorrhage neonatal24.07.04.024; 18.04.16.001; 17.08.01.0480.000019%Not Available
Convulsive threshold lowered17.12.03.0230.000019%Not Available
Cyanosis neonatal22.11.02.003; 18.04.09.0060.000038%Not Available
Delusion of grandeur19.10.01.0040.000019%Not Available
Delusional disorder, erotomanic type19.03.03.0040.000028%Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000019%Not Available
Hypermetropia06.02.04.0100.000038%Not Available
Impulsive behaviour19.18.01.0010.000137%Not Available
Neonatal asphyxia22.11.02.006; 18.04.15.0050.000047%Not Available
Neonatal respiratory depression22.11.02.009; 18.04.17.0020.000019%Not Available
The 33th Page    First    Pre   33 34 35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene